708 Loss of ryanodine receptor calcium release channels in Alzheimer's disease brain

1996 ◽  
Vol 17 (4) ◽  
pp. S176 ◽  
Author(s):  
C. O' Neill ◽  
M. Kelliher ◽  
R. Ravid
2000 ◽  
Vol 28 (1) ◽  
pp. A18-A18
Author(s):  
C. O'Neill ◽  
J. Fastbom ◽  
R. Cowburn ◽  
M. Carmody ◽  
T.G. Ohm ◽  
...  

2020 ◽  
Vol 18 (9) ◽  
pp. 668-676 ◽  
Author(s):  
Yun Shi ◽  
Yong Wang ◽  
Huafeng Wei

Dantrolene, a ryanodine receptor antagonist, is primarily known as the only clinically acceptable and effective treatment for Malignant Hyperthermia (MH). Inhibition of Ryanodine Receptor (RyR) by dantrolene decreases the abnormal calcium release from the Sarcoplasmic Reticulum (SR) or Endoplasmic Reticulum (ER), where RyR is located. Recently, emerging researches on dissociated cells, brains slices, live animal models and patients have demonstrated that altered RyR expression and function can also play a vital role in the pathogenesis of Alzheimer’s Disease (AD). Therefore, dantrolene is now widely studied as a novel treatment for AD, targeting the blockade of RyR channels or another alternative pathway, such as the inhibitory effects of NMDA glutamate receptors and the effects of ER-mitochondria connection. However, the therapeutic effects are not consistent. In this review, we focus on the relationship between the altered RyR expression and function and the pathogenesis of AD, and the potential application of dantrolene as a novel treatment for the disease.


2014 ◽  
Vol 114 (7) ◽  
pp. 1114-1124 ◽  
Author(s):  
Hyun Seok Hwang ◽  
Florentin R. Nitu ◽  
Yi Yang ◽  
Kafa Walweel ◽  
Laetitia Pereira ◽  
...  

2017 ◽  
Vol 134 (5) ◽  
pp. 749-767 ◽  
Author(s):  
Alain Lacampagne ◽  
Xiaoping Liu ◽  
Steven Reiken ◽  
Renaud Bussiere ◽  
Albano C. Meli ◽  
...  

2012 ◽  
Vol 33 (5) ◽  
pp. 1001.e1-1001.e6 ◽  
Author(s):  
Angela M. Bruno ◽  
Jeff Y. Huang ◽  
David A. Bennett ◽  
Robert A. Marr ◽  
Michelle L. Hastings ◽  
...  

1996 ◽  
Vol 76 (4) ◽  
pp. 1027-1071 ◽  
Author(s):  
J. L. Sutko ◽  
J. A. Airey

Complexities in calcium signaling in eukaryotic cells require diversity in the proteins involved in generating these signals. In this review, we consider the ryanodine receptor (RyR) family of intracellular calcium release channels. This includes species, tissue, and cellular distributions of the RyRs and mechanisms of activation, deactivation, and inactivation of RyR calcium release events. In addition, as first observed in nonmammalian vertebrate skeletal muscles, it is now clear that more than one RyR isoform is frequently coexpressed within many cell types. How multiple ryanodine receptor release channels are used to generate intracellular calcium transients is unknown. Therefore, a primary focus of this review is why more than one RyR is required for this purpose, particularly in a tissue, such as vertebrate fast-twitch skeletal muscles, where a relatively simple and straightforward change in calcium would appear to be required to elicit contraction. Finally, the roles of the RyR isoforms and the calcium release events they mediate in the development of embryonic skeletal muscle are considered.


ChemMedChem ◽  
2018 ◽  
Vol 13 (18) ◽  
pp. 1957-1971 ◽  
Author(s):  
Ken Robinson ◽  
Christopher J. Easton ◽  
Angela F. Dulhunty ◽  
Marco G. Casarotto

Sign in / Sign up

Export Citation Format

Share Document